Key points are not available for this paper at this time.
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease largely due to the lack of effective treatments that overcome the tumor drug resistance. Oncogenic KRAS mutation contribute to most PDAC and drive multiple metabolic pathways to promote tumor growth. Despite this overarching role of KRAS, inhibition of KRAS/MAPK pathway often lead to resistance by yet unclear mechanism. Here we find that the pharmacological inhibition of KRAS/MAPK pathway induces distinct responses in various pancreatic cancer cells. Specifically, while KRAS/MAPK inhibition suppressed growth in some cells, the same treatment induced or did not change the growth of other cell lines and also selectively impacted cell migration. In addition, metabolic activities were suppressed in cells where growth was suppressed or not changed but was accelerated where KRAS/MAPK inhibition induced growth. Analysis of gene expression profile of human PDAC and KRAS-driven mouse tumors identified nutrient transporters that are upregulated KRAS induction but also upregulated upon KRAS inhibition. Our study reveals context-dependent response to KRAS inhibition in pancreatic cancer and suggest targeting nutrient transporters to overcome therapeutic resistance. Citation Format: Laiba Shiekh, Matthew Cheung, Linyuhui Zheng, Erica Marlette, Chiamaka J. Ezeh, Don-Gerard Conde, Zeribe C. Nwosu. Targeting KRAS selectively induce metabolic reprogramming in pancreatic cancer abstract. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research; 2024 Sep 15-18; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84 (17 Suppl₂): Abstract nr C017.
Shiekh et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: